A research team at the University of Basel has discovered immune cells resident in the lungs that persist long after a bout of flu. Experiments with mice have shown that these helper cells improve the immune response to reinfection by a different strain of the flu virus. The discovery could yield approaches to developing longer-lasting vaccinations against quickly-mutating viruses.
At the start of the coronavirus pandemic, some already began to raise the question of how long immunity lasts after weathering SARS-CoV-2. The same question has now arisen regarding the COVID-19 vaccination. A key role is played by immunological memory—a complex interplay of immune cells, antibodies and signaling substances that allows the body to fight off known pathogens very efficiently.
Researchers led by Professor Carolyn King from the University of Basel’s Department of Biomedicine have now identified a diverse group of immune cells in the lungs that are key to the defense against reinfection by flu viruses. The same could be true of reinfection by other pathogens that cause respiratory diseases.
In experiments with mice, the researchers characterized a group of memory T cells in lung tissue that remain for a long time after a bout of flu. The team reports on these “T resident helper cells” in the peer-reviewed journal Science Immunology.
Reservoir inside tissue
“Relatively little is known about memory T cells that remain in tissue,” explained Nivedya Swarnalekha, co-first author of the study. Previous studies have focused on memory cells in blood and lymphatic tissue. “But it makes sense that the body keeps a reservoir of these cells in the tissues affected by the infection, where the same or similar pathogens could invade again.”
In their study, the researchers describe two types of T helper cells in the lungs. One type releases signaling substances in case of reinfection to equip other immune cells with deadlier “weapons” in the fight against the pathogen. The other type, previously characterized primarily in lymphatic tissue and thought to be absent in lung tissue, assists antibody-producing immune cells (B cells) and localizes closely with them in the lung.
The researchers were able to show that the presence of these cells in the direct proximity of the antibody-producing B cells led to a more efficient immune response against a different flu virus.
Starting point for long-term vaccine protection
“These T helper cells could be an interesting starting point for longer-lasting flu vaccinations,” says David Schreiner, the other co-first author of the study, adding that it might be possible, for example, to supplement vaccines with agents that promote the formation of these T helper cells which migrate into the tissue. To that end, further research and development are needed.
Protective immunity against SARS-CoV-2 could last eight months or more
“T resident helper cells promote humoral responses in the lung,” Science Immunology (2021). immunology.sciencemag.org/look … 6/sciimmunol.abb6808
Immune cells discovered in the lungs improve virus defense (2021, January 8)
retrieved 8 January 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022